Familial mutation of NR5A1/SF-1 gene associated with 46,XY DSD and spleen agenesis: a new syndrome?

Pascal Philibert, Estelle Aubry, Francis Poulat, Françoise Audran, Maryse Cartigny, Françoise Paris, Charles Sultan, Sylvie Manouvrier-Hanu

4 Département de Biochimie et Hormonologie, CHRU de Montpellier, Montpellier, France; 5 Université de Montpellier, Montpellier, France; 6 Institut de Génétique Humaine - CNRS UPR1142, Montpellier, France; 7 Service de Chirurgie Viscère Pédiatrique, CHU Lille, France; 8 Service d’Endocrinologie Pédiatrique, CHU Lille, France; 9 Clinique de Génétique Guy Fontaine, CHU Lille, France; 10 Université de Lille, CHU Lille, EA 7364 – RADEME – Maladies Rares du Développement et du MÉtabolisme, Lille, France

Background:
A recent report (JCI, 2014) described a new homozygous NR5A1/SF-1 mutation in a patient with 46,XY DSD and spleen agenesis. To date, no other data have confirmed this association, raising the hypothesis of fortuity.

Case presentation and method:
We had the opportunity to study an adolescent girl referred for virilization during puberty. At age 12.5 years, she presented voice deepening, moustache and clitoral hypertrophy. She was overweight. Biological investigations showed high plasma testosterone (2ng/ml) and gonadotropin levels and undetectable levels of AMH and inhibin B. The family history revealed that her father had surgery for hypospadias in infancy. At 45 years, he was hospitalized for purpura fulminans, at which time asplenia was diagnosed.

Figure 1: Electrophoregrams of Patient, her sister, her father and grand-parent

Results:
Sonography and MRI showed three small residues which were evoked for spleen. Genetic investigation identified a new heterozygous NR5A1 gene mutation (c.1227C>A) within exon 7. This mutation creates a premature stop codon (p.Tyr409X) and results, if expressed, in a truncated protein (Fig. 2). The father’s genetic analysis revealed the same mutation. However, this mutation was absent from both paternal grandparents. In vitro assays of this mutation are in progress to investigate the mutant transactivation capabilities on Tesco (Sertoli), Cyp11a1 (Leydig) and TLX1 (spleen) promoters.

Figure 2: Cartoon showing the WT and mutant protein

Conclusion:
In mice, SF-1 gene invalidation leads to XY complete gonadal dysgenesis, adrenal agenesis and abnormal spleen development. In human, an SF-1 mutation may lead to both gonadal dysgenesis and spleen hypotrophy, raising the hypothesis of a new syndrome. These data underline the usefulness of spleen function investigation in all patients with SF-1 gene mutation.

Reference: